Advances in monoclonal antibody therapy for colorectal cancer

As a disease phenomenon, the existence and recognition of cancer can be traced back to the medical literature long ago. However, the modern scientific understanding and classification of CRC are gradually formed with the deepening of medical research. Through long-term clinical observation, pathological research and the development of molecular biology technology, scientists have gradually revealed the pathogenesis, genetic characteristics and treatment of CRC. As for the invention of mAb for the treatment of CRC, it is the product of rapid development of biomedical technology in recent decades. In the treatment of CRC, a variety of mAb have been developed and applied clinically, such as monoclonal drugs targeting key signaling pathways such as EGFR and VEGF. The invention and application of these drugs provide new treatment options and hopes for CRC patients, and allow patients to have more choices to choose their own drugs to avoid some side effects during treatment.